1. Home /
  2. Biotechnology

Biotechnology

Incyte Expected to Earn 17 Cents a Share

Incyte Expected to Earn 17 Cents a Share

Incyte revenue expected to rise 9.5% to $486.2 million.

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.

It's a Stock Picker's Delight Right Now

It's a Stock Picker's Delight Right Now

With cash levels high, those players who are not well-positioned for upside action are scrambling to put money to work and are helping to propel prices higher.

FDA Cracks Down On Misleading Dietary Supplements

FDA Cracks Down On Misleading Dietary Supplements

The agency delivers 17 different warnings to companies advertising that their supplements help treat Alzheimer's, diabetes and cancer.

Gilead Sciences Drops Following Earnings Miss

Gilead Sciences Drops Following Earnings Miss

The biotech company reports downside bottom-line results, though it beats on revenue.

Array BioPharma Surges as Loss Is Narrower Than Expected

Array BioPharma Surges as Loss Is Narrower Than Expected

The cancer drugmaker post narrower-than-expected losses for the quarter and strong revenue growth.

Merck Is Named No. 1 Pharma Pick at Bank of America

Merck Is Named No. 1 Pharma Pick at Bank of America

Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.

Report Says Starboard Value Takes Stake in Bristol-Myers

Report Says Starboard Value Takes Stake in Bristol-Myers

Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.

Beyond Alphabet: 3 Other Notable Companies Reporting Results After the Bell

Beyond Alphabet: 3 Other Notable Companies Reporting Results After the Bell

Seagate, Hartford Financial and Gilead are set to report after the bell Monday.

2 Small-Cap Stocks That Are Still a Bargain

2 Small-Cap Stocks That Are Still a Bargain

Despite the January rally, this biotech name and building materials firm still have further to rise.